Comparison of methods for the assessment of HIV-1 susceptibility to broadly neutralizing antibodies

Broadly neutralizing antibodies (bNAbs) are being developed for the prevention, treatment, and cure of HIV-1. The efficacy of a bNAb is dependent upon the susceptibility of an individual’s virus to the administered bNAb, which can be assessed phenotypically or genotypically. Both methods require cut-offs for susceptibility classification; however, clinical cut-offs for bNAb susceptibility have not been established. In this study, we assessed susceptibility to the two HIV-1 bNAbs 3BNC117 and 10–1074 among 59 newly diagnosed people living with HIV-1 using one phenotypic and four genotypic susceptibility assessment methods. We show that the methods employed and cut-offs assigned can greatly affect the susceptibility prediction. By evaluating the decay in plasma viral load for participants receiving 3BNC117 at ART initiation, clinically relevant cut-offs for susceptibility were identified using an exploratory approach, and application of these cut-offs resulted in 68%–76% of the viruses being correctly classified. No clinical data were available to set cut-offs for susceptibility to 10-1074. Instead, the methods were compared, and consensus-derived cut-offs were set, which resulted in concordant susceptibility assessments for 84% of the participants. In conclusion, our study underlines the importance of the chosen method and cut-off when assessing an individual’s virus susceptibility to HIV-1 bNAbs. Furthermore, we propose cut-offs for bNAb susceptibility to guide the design of future clinical trials.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.1911783
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparison of methods for the assessment of HIV-1 susceptibility to broadly neutralizing antibodies

Jacqueline D. Reeves, Maibritt Mardahl, Martin Tolstrup, Rolf Kaiser et al.
3 links
Frontiers in Immunology
HIV Research and Treatment
article

Comparison of methods for the assessment of HIV-1 susceptibility to broadly neutralizing antibodies

Jacqueline D. Reeves, Maibritt Mardahl, Martin Tolstrup, Rolf Kaiser, Martin Pirkl, Víctor Ramos, Henrik Støvring, Christos J. Petropoulos, Ole Schmeltz Søgaard, Jesper Damsgaard Gunst, Marie Høst Pahus
article en

Abstract

Broadly neutralizing antibodies (bNAbs) are being developed for the prevention, treatment, and cure of HIV-1. The efficacy of a bNAb is dependent upon the susceptibility of an individual’s virus to the administered bNAb, which can be assessed phenotypically or genotypically. Both methods require cut-offs for susceptibility classification; however, clinical cut-offs for bNAb susceptibility have not been established. In this study, we assessed susceptibility to the two HIV-1 bNAbs 3BNC117 and 10–1074 among 59 newly diagnosed people living with HIV-1 using one phenotypic and four genotypic susceptibility assessment methods. We show that the methods employed and cut-offs assigned can greatly affect the susceptibility prediction. By evaluating the decay in plasma viral load for participants receiving 3BNC117 at ART initiation, clinically relevant cut-offs for susceptibility were identified using an exploratory approach, and application of these cut-offs resulted in 68%–76% of the viruses being correctly classified. No clinical data were available to set cut-offs for susceptibility to 10-1074. Instead, the methods were compared, and consensus-derived cut-offs were set, which resulted in concordant susceptibility assessments for 84% of the participants. In conclusion, our study underlines the importance of the chosen method and cut-off when assessing an individual’s virus susceptibility to HIV-1 bNAbs. Furthermore, we propose cut-offs for bNAb susceptibility to guide the design of future clinical trials.

Frontiers in ImmunologyVol. 17
University of Cologne (DE), Aarhus University (DK), LabCorp (United States) (US), Aarhus University Hospital (DK), University Hospital Cologne (DE), Rockefeller University (US)
Good health and well-being
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon